Pregled bibliografske jedinice broj: 1110641
Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram
Distinct association of plasma BDNF concentration and cognitive function in depressed patients treated with vortioxetine or escitalopram // Psychopharmacology, 238 (2021), 2; 1575-1584 doi:10.1007/s00213-021-05790-2 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1110641 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Distinct association of plasma BDNF concentration
and cognitive function in
depressed patients treated with vortioxetine or
escitalopram
(Distinct association of plasma BDNF concentration
and cognitive
function in depressed patients treated with
vortioxetine or
escitalopram)
Autori
Šagud, Marina ; Nikolac Perković, Matea ; Dvojković, Anja ; Jakšić, Nenad ; Vuksan-Ćusa, Bjanka ; Živković, Maja ; Kušević, Zorana ; Mihaljević-Peleš, Alma ; Pivac, Nela
Izvornik
Psychopharmacology (0033-3158) 238
(2021), 2;
1575-1584
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
vortioxetine ; escitalopram ; cognition ; memory ; executivefunction ; BDNF ; depression ; MDD
Sažetak
Cognitive dysfunction is frequent in major depressive disorder (MDD), and brain-derived neurotrophicfactor (BDNF) is involved both in regulation of cognition and in therapeutic response in MDD. The aim of this study was to determine if baseline plasma BDNF might predict change in cognitive function in MDD patients treated with vortioxetine orescitalopram, and whether the alterations in BDNF levels correlate with changes in cognitive performance during treatment. Drug-naive or drug-free patients with MDD (N=121) were sampled and evaluated at baseline and 4 weeks after treatment initiation with vortioxetine or escitalopram. Cognitive function was evaluated using the F-A-S test, Digit Span test, and Digit Symbol Coding test. Plasma BDNF was determined using ELISA. The results of the study indicate that both vortioxetine (V) and escitalopram (E) improved cognitive functions evaluated with F-A-S test (V: p<0.001 ; r=−0.427, E: p<0.001 ; r=−0.370), Digit Symbol Coding test (V: p<0.001 ; r=−0.706, E: p<0.001 ; r=−0.435), and Digit Span test-backwardspan (V:p=0.001 ; r=−0.311, E:p=0.042 ; r=−0.185), while only vortioxetine(p<0.001 ; r=−0.325) improved cognition evaluated with the Digit Span test- forward span. A moderate positive correlation between pretreatment plasma BDNF levels and improvement in cognitive performance was only detected in patients treated with vortioxetine (delta F-A-S test: p=0.011 ; r=0.325, delta Digit Span test-forward span: p=0.010, r=0.326). These results suggest that higher baseline plasma BDNF levels might be associated with improvements in verbal fluency and working memory in vortioxetine, but not escitalopram treated patients. Vortioxetine treatment was superior in simple attention efficiency.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
MZOS-098-0982522-2455 - Molekularna podloga i liječenje psihijatrijskih i stresom izazvanih poremećaja (Pivac, Nela, MZOS ) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb,
Klinika za psihijatriju Vrapče,
Klinički bolnički centar Zagreb
Profili:
Zorana Kušević
(autor)
Alma Mihaljević-Peleš
(autor)
Matea Nikolac Perković
(autor)
Bjanka Vuksan-Ćusa
(autor)
Anja Dvojković
(autor)
Marina Šagud
(autor)
Nela Pivac
(autor)
Maja Živković
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE